Skip to content

Verification Test on Effects of Home Esthetic Machine (SAQINA Corebelle) Use on Skin Function - Open-label Before-and-After Comparison Test -

Verification Test on Effects of Home Esthetic Machine (SAQINA Corebelle) Use on Skin Function - Open-label Before-and-After Comparison Test - - Verification Test on Effects of Home Esthetic Machine (SAQINA Corebelle) Use on Skin Function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000060652
Enrollment
25
Registered
2026-02-12
Start date
2026-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Every day, perform approximately 15 minutes of skincare using the test equipment and the provided cleansers, facial washes, and cosmetics.

Sponsors

TES Holdings Co., Ltd.
Lead Sponsor
COMET ELECTRIC Co., Ltd.
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Women aged 35 to 64 at the time of obtaining consent to participate in the trial. 2) Healthy individuals with no chronic physical conditions, including skin diseases. 3) Individuals who are aware of skin concerns such as dryness. 4) Individuals capable of performing daily skin care at home using a home beauty device for approximately 15 minutes. 5) Individuals who have received sufficient explanation regarding the purpose and content of this trial, possess the capacity to consent, voluntarily volunteer to participate after fully understanding, and can provide written consent to participate in this trial. 6) Individuals who can attend the designated examination date and undergo the examination. 7) Individuals deemed suitable for participation in this trial by the principal investigator.

Exclusion criteria

Exclusion criteria: Individuals 1) currently suffering from any disease and undergoing drug therapy. 2) using implantable medical electronic devices such as pacemakers, wearable medical electronic devices such as electrocardiographs, or life-sustaining electronic devices such as artificial hearts. 3) with cosmetic allergies (cosmetic dermatitis) or those at risk of developing such allergies due to switching cosmetics. 4) receiving hormone replacement therapy. 5) with skin disease symptoms such as atopic dermatitis. 6) with a history of ingesting or applying medications for disease treatment within the past month. 7) with a history or current condition of serious disorders of the digestive organs, liver, kidneys, heart, lungs, blood, or mental disorders. 8) with a BMI of 30.0 kg/m2 or higher. 9) whose average weekly alcohol consumption exceeds 20 g of pure alcohol per day for women. 10) with smoking habits. 11) who may work night shifts or alter their daily routines during the trial period. 12) who may experience facial symptoms such as redness, itching, dryness, or swelling during the trial period due to seasonal allergies like hay fever. Also, individuals who may take anti-allergy medications or use nasal sprays. 13) who cannot avoid intentional exposure to direct sunlight, such as through sunbathing, during the trial period. 14) who regularly use home aesthetic devices or receive aesthetic treatments. 15) with a history of cosmetic procedures or treatments, such as aesthetic treatments or hyaluronic acid injections, on the evaluation site within the past 6 months. 16) who are pregnant, breastfeeding, or may become pregnant during the trial period. 17) currently participating in another human clinical trial, or individuals who have not completed 3 months since participation in another human clinical trial. 18) Other individuals deemed unsuitable for this trial by the principal investigator.

Design outcomes

Primary

MeasureTime frame
*Efficacy Evaluation Items 1) Stratum corneum moisture content 2) Dermal moisture content 3) Trans epidermal water loss (TEWL) 4) Skin viscoelasticity 5) Collagen score 6) Skin texture evaluation (skin surface and morphological assessment) 7) VISIA facial image analysis 8) Skin tone evaluation 9) Visual wrinkle grade assessment 10) Subjective questionnaire *Safety Evaluation Items 1) Daily Activity Log 2) Physician Interview and Adverse Event Investigation

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026